| Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression LG Hudson, R Zeineldin, MS Stack Clinical & experimental metastasis 25, 643-655, 2008 | 234 | 2008 |
| Role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells R Zeineldin, M Al-Haik, LG Hudson Nano letters 9 (2), 751-757, 2009 | 93 | 2009 |
| Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer PS Kim, S Djazayeri, R Zeineldin Gynecologic oncology 120 (3), 393-403, 2011 | 86 | 2011 |
| Targeting the EGF receptor for ovarian cancer therapy R Zeineldin, CY Muller, MS Stack, LG Hudson Journal of oncology 2010, 2010 | 86 | 2010 |
| PEA3 is necessary for optimal epidermal growth factor receptor–stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells KD Cowden Dahl, R Zeineldin, LG Hudson Molecular Cancer Research 5 (5), 413-421, 2007 | 83 | 2007 |
| Down-regulation of integrin α2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation Y Ning, R Zeineldin, Y Liu, M Rosenberg, MS Stack, LG Hudson Cancer research 65 (20), 9280-9286, 2005 | 67 | 2005 |
| Activated epidermal growth factor receptor in ovarian cancer LG Hudson, R Zeineldin, M Silberberg, MS Stack Ovarian Cancer: Second Edition, 203-226, 2010 | 62 | 2010 |
| Effect of chirality and length on the penetrability of single-walled carbon nanotubes into lipid bilayer cell membranes AA Skandani, R Zeineldin, M Al-Haik Langmuir 28 (20), 7872-7879, 2012 | 50 | 2012 |
| Using bicellar mixtures to form supported and suspended lipid bilayers on silicon chips R Zeineldin, JA Last, AL Slade, LK Ista, P Bisong, MJ O'Brien, SRJ Brueck, ... Langmuir 22 (19), 8163-8168, 2006 | 48 | 2006 |
| Biomimetic silica microspheres in biosensing S Chemburu, K Fenton, GP Lopez, R Zeineldin Molecules 15 (3), 1932-1957, 2010 | 47 | 2010 |
| Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III R Zeineldin, M Rosenberg, D Ortega, C Buhr, MG Chavez, MS Stack, ... Molecular Carcinogenesis: Published in cooperation with the University of …, 2006 | 43 | 2006 |
| Detection of membrane biointeractions based on fluorescence superquenching R Zeineldin, ME Piyasena, LA Sklar, D Whitten, GP Lopez Langmuir 24 (8), 4125-4131, 2008 | 33 | 2008 |
| Epithelial cell migration in response to epidermal growth factor R Zeineldin, LG Hudson Epidermal Growth Factor: Methods and Protocols, 147-158, 2006 | 27 | 2006 |
| Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers R Zeineldin US Patent 9,532,949, 2017 | 24 | 2017 |
| Superquenching as a detector for microsphere‐based flow cytometric assays R Zeineldin, ME Piyasena, TS Bergstedt, LA Sklar, D Whitten, GP Lopez Cytometry Part A 69 (5), 335-341, 2006 | 24 | 2006 |
| Biosensors based on release of compounds upon disruption of lipid bilayers supported on porous microspheres ME Piyasena, R Zeineldin, K Fenton, T Buranda, GP Lopez Biointerphases 3 (2), 38-49, 2008 | 22 | 2008 |
| Detection systems utilizing supported lipid bilayers GP Lopez, R Zeineldin, ME Piyasena US Patent 7,514,267, 2009 | 17 | 2009 |
| The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2 R Zeineldin, Y Ning, LG Hudson Journal of Histochemistry & Cytochemistry 58 (6), 529-541, 2010 | 16 | 2010 |
| Cancer nanotechnology: opportunities for prevention, diagnosis, and therapy R Zeineldin, J Syoufjy Cancer Nanotechnology: Methods and Protocols, 3-12, 2017 | 13 | 2017 |
| Nanotechnology for cancer screening and diagnosis R Zeineldin Biomaterials for cancer therapeutics, 137-164, 2013 | 13 | 2013 |
